Edition:
United Kingdom

People: Audentes Therapeutics Inc (BOLD.OQ)

BOLD.OQ on NASDAQ Stock Exchange Global Market

39.14USD
23 Jul 2019
Change (% chg)

$0.34 (+0.88%)
Prev Close
$38.80
Open
$39.05
Day's High
$39.38
Day's Low
$38.10
Volume
94,542
Avg. Vol
154,936
52-wk High
$42.04
52-wk Low
$18.00

Soloway, Thomas 

Mr. Thomas P. Soloway is Chief Financial Officer, Executive Vice President of the Company. He previously served as our Senior Vice President from October 2015 to February 2019. Prior to joining us, Mr. Soloway served as the Senior Vice President and Chief Financial Officer of Ascendis Pharma A/S from January 2014 until September 2015. Prior to Ascendis, Mr. Soloway co-founded Transcept Pharmaceuticals, Inc., a biotechnology company, in 2002. At Transcept, Mr. Soloway held various positions, including Chief Financial Officer and Executive Vice President, Chief Operating Officer. Prior to joining Transcept, Mr. Soloway financed and advised early stage healthcare and life sciences companies as a Principal at Montreux Equity Partners. Mr. Soloway holds a B.S. from the University of Southern California and an M.B.A. from Georgetown University.

Basic Compensation

Total Annual Compensation, USD 397,950
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 127,360
Fiscal Year Total, USD 525,310

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --